

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Nivolumab for treating unresectable advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u> Bristol-Myers Squibb (nivolumab)</p> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • Cancer Black Care • Cancer Equality • Cancer 52 • Equalities National Council • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie’s Centres • Marie Curie • Muslim Council of Britain • Oesophageal Patients Association • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association of Surgeons of Great Britain and Ireland • British Association of Surgical Oncology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society of Gastroenterology • Cancer Research UK 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Society of Gastroenterology • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (docetaxel, irinotecan, paclitaxel) • Celgene (paclitaxel) • Genzyme Therapeutics (docetaxel) • Hospira UK (docetaxel, irinotecan, paclitaxel)

Provisional matrix for the health technology appraisal of nivolumab for unresectable, advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

Issue date: September 2019

© National Institute for Health and Care Excellence 2019. All rights reserved

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Durham Dales, Easington and Sedgefield CCG • NHS Southport and Formby CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Medac (docetaxel, irinotecan paclitaxel) • Pfizer (irinotecan) • Seacross Pharmaceuticals (docetaxel, irinotecan) • Servier Laboratories (irinotecan) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Grampian Gastro-Oesophageal Cancer Research Fund • Guts UK • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Research Institute of the Care of the Elderly <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Provisional matrix for the health technology appraisal of nivolumab for unresectable, advanced oesophageal cancer when standard chemotherapy has failed [ID1249]

Issue date: September 2019

© National Institute for Health and Care Excellence 2019. All rights reserved

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.